Articles

Rationale and design of the REMBRANDT trial: A phase 3 study to evaluate the effect of obicetrapib/ezetimibe on coronary plaque characteristics

McCarthy CP, Ballantyne CM, Blankstein R, et al.

First published: July 17, 2025  DOI: 10.1016/j.ahj.2025.07.012